Recent Updates
Recently added Catalysts
NPCE Positive Sentiment

NeuroPace to Participate in 2026 Cantor Global Healthcare Conference

Tuesday, September 1, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: NeuroPace, Inc. announced its participation in the 2026 Cantor Global Healthcare Conference. The management team will engage in a fireside chat on September 9 and conduct one-on-one meetings with investors. This event highlights NeuroPace's commitment to addressing epilepsy through innovative medical devices.

Market Sentiment Analysis

POSITIVE FACTORS

  • Participation in a prominent healthcare conference.
  • Opportunity for management to engage with investors.
  • Focus on transforming lives of people with epilepsy.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Cash runway
~39 mo
Minimal dilution risk
Lead asset
external Responsive Neurostimulator System
Phase 2 · Epilepsy

Full Press Release Details

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that its management team will participate in the upcoming 2026 Cantor Global Healthcare Conference. NeuroPace management will participate in a fireside chat discussion on Wednesday, September 9 at 10:55am EDT, and host one-on-one meetings with investors during the conference. The fireside chat will be accessible via a

Frequently Asked Questions

What is the date of the Cantor Global Healthcare Conference?

The conference will take place on September 9, 2026.

What will NeuroPace management do at the conference?

They will participate in a fireside chat and hold one-on-one meetings with investors.

What is NeuroPace focused on?

NeuroPace is focused on transforming the lives of people living with epilepsy.

How can I access the fireside chat?

The fireside chat will be accessible via a specified platform during the conference.

ShareAdd on Google
Tags: NPCE Viatris Investor Conferences Healthcare NeuroPace Cantor Global Healthcare Conference epilepsy investor meetings medical device
Last updated: Sep 1, 2026

Biotech snapshot

Cash runway
$52M liquidity · $1M/mo burn
~39 mo
Minimal dilution risk
Lead asset
external Responsive Neurostimulator SystemPhase 2
Epilepsy →